Is loss of function of PCSK9 a key in the protection against atherosclerotic cardiovascular disease?

被引：0
|
作者：
Reuwer, AQ [1 ]
机构：
[1] Univ Utrecht, Fac Med, NL-3508 TC Utrecht, Netherlands
来源：
CLINICAL GENETICS | 2006年 / 70卷 / 01期
关键词：
D O I：
10.1111/j.1399-0004.2006.0627b.x
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：15 / 17
页数：3
相关论文
共 50 条
  • [1] PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
    Delialis, Dimitrios
    Dimopoulou, Maria-Angeliki
    Papaioannou, Maria
    Kotsira, Georgia
    Maneta, Eleni
    Mavraganis, Georgios
    Loutos, Christos
    Georgiopoulos, Georgios
    Stamatelopoulos, Kimon
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (23) : 1802 - 1824
  • [2] PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease
    Bittner, Vera A.
    Giugliano, Robert P.
    Brinton, Eliot A.
    Guyton, John R.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 835 - 843
  • [3] PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort
    Small, Aeron M.
    Huffman, Jennifer E.
    Klarin, Derek
    Lynch, Julie A.
    Assimes, Themistocles
    DuVall, Scott
    Sun, Yan, V
    Shere, Labiba
    Natarajan, Pradeep
    Gaziano, Michael
    Rader, Daniel J.
    Wilson, Peter W. F.
    Tsao, Philip S.
    Chang, Kyong-Mi
    Cho, Kelly
    O'Donnell, Christopher J.
    Casas, Juan P.
    Damrauer, Scott M.
    PLOS ONE, 2020, 15 (11):
  • [4] Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
    Wojcik, Cezary
    POSTGRADUATE MEDICINE, 2017, 129 (08) : 801 - 810
  • [5] Effect of Genetic Variation in Loss of Function Variants in PCSK9 on Atherosclerotic Vascular Disease
    Small, Aeron M.
    Huffman, Jennifer E.
    Klarin, Derek
    Lynch, Julie
    Sun, Yan
    Lee, Jennifer S.
    Assimes, Thermistocles
    Miller, Donald
    Freiberg, Matthew
    Gaziano, J. Michael
    Rader, Daniel J.
    Wilson, Peter W.
    Cho, Kelly
    Tsao, Phil
    Chang, Kyong-Mi
    Casas, J. P.
    O'Donnell, Christopher J.
    Damrauer, Scott M.
    CIRCULATION, 2018, 138
  • [6] Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy
    Krittanawong, Chayakrit
    Khawaja, Muzamil
    Rosenson, Robert S.
    Amos, Christopher, I
    Nambi, Vijay
    Lavie, Carl J.
    Virani, Salim S.
    CURRENT PROBLEMS IN CARDIOLOGY, 2022, 47 (07)
  • [7] PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease
    Landmesser, Ulf
    CARDIOVASCULAR RESEARCH, 2017, 113 (08) : E24 - E25
  • [8] PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
    Sobati, Saeideh
    Shakouri, Amir
    Edalati, Mahdi
    Mohammadnejad, Daryoush
    Parvan, Reza
    Masoumi, Javad
    Abdolalizadeh, Jalal
    ADVANCED PHARMACEUTICAL BULLETIN, 2020, 10 (04) : 502 - 511
  • [9] PCSK9: A Key Modulator of Cardiovascular Health
    Seidah, Nabil G.
    Awan, Zuhier
    Chretien, Michel
    Mbikay, Majambu
    CIRCULATION RESEARCH, 2014, 114 (06) : 1022 - 1036
  • [10] Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease
    Dave L. Dixon
    Lauren G. Pamulapati
    John D. Bucheit
    Evan M. Sisson
    Shawn R. Smith
    Caroline J. Kim
    George F. Wohlford
    Jonah Pozen
    Current Atherosclerosis Reports, 2019, 21
12345